STOCK TITAN
  1. Home
  2. News
  3. ARDX

Ardelyx to Webcast Virtual Analyst Day

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

FREMONT, Calif., Nov. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that it will hold a virtual Analyst Day on Thursday, November 12, 2020, from 9:30 a.m. to 12:00 p.m. ET. This year's event will focus on the company's launch and commercialization plans in anticipation of the potential approval of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Additionally, the company will review its pipeline therapeutic for hyperkalemia.

The management team will be joined by:

  • German Hernandez, M.D., FASN, FACP, associate nephrologist at El Paso Kidney Specialists and clinical associate professor of medicine at Texas Tech University Health Sciences Center, will review tenapanor's unique profile.
  • Jennifer Robinson, president of Spherix Global Insights, will present data on the challenges of treating hyperphosphatemia in patients with CKD on dialysis.
  • Douglas Paul, PharmD, Ph.D., vice president and partner at MME, will discuss value perceptions across payers, patients and healthcare professionals.

A live webcast of the event will be available on the Ardelyx website via the Events and Presentations page under the investor relations section at https://ir.ardelyx.com/events-and-presentations.

About Ardelyx, Inc.
Ardelyx is focused on developing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiovascular diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA goal date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue program, for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-webcast-virtual-analyst-day-301167749.html

SOURCE Ardelyx

Stock ARDX logo
Ardelyx, Inc.

NASDAQ:ARDX

ARDX Rankings

#1992 Ranked by Market Cap
#88 Ranked by Stock Gains
N/A Ranked by Dividends

ARDX Latest News

May 16, 2024
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
May 14, 2024
Ardelyx, Inc. Reports Employment Inducement Grants
May 7, 2024
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
May 2, 2024
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
May 1, 2024
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings

ARDX Stock Data

1.83B
226.69M
1.95%
60.33%
15.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
FREMONT

About ARDX

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.